Clinical Trial Update: A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating alvelestat (MPH966) versus placebo in participants with alpha1-antitrypsin-related COPD has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency
• Chronic Obstructive Pulmonary Disease
• Emphysema

Drugs mentioned

• Alvelestat (alvelestat)

Snippet

Sponsor: Mereo BioPharma | Conditions: Alpha 1-Antitrypsin Deficiency, Emphysema | Phase 2 | Status: COMPLETED